Facial Atopic Dermatitis and Atopic Keratoconjunctivitis (AKC) - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL | oDigger

Facial Atopic Dermatitis and Atopic Keratoconjunctivitis (AKC) - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL

Promote this offer through the SmartAdv Affiliate Network

Offer Details:


Offer Name:

Facial Atopic Dermatitis and Atopic Keratoconjunctivitis (AKC) - Clinical Study [US,CA] (Email,Social,Banner,Native,Push,SEO,Search,Brand Bidding) - CPL

Preview:

Preview Landing Page

Categories:

Health

Network:

SmartAdv

Status:

Active

Last Updated:

Dec 26, 2024

Date Added:

Dec 26, 2024

Payouts:

$125.00 / cpa

Countries:

US / CA
Join SmartAdv

Affiliate Offer Description:

You must be a member of SmartAdv to promote this offer. Click Here to join their network.
Conversion Point: Valid Form Fill Ages: 18+ Gender: Any Compensation: Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated up to $1575 for 7 visits or $2475 for 11 visits for time and travel. GEO: US Only Traffic Allowed: Email, Social, Banner, Native, Push, SEO, Search, Brand Bidding No Incent No Co-Reg No Survey No SMS No Adult Send ad creatives and LP to AM for approval Forbidden traffic types/false Advertisements Will NOT Be Paid For Fake/false celebrity ads/endorsements are strictly prohibited Qualifications: - Must currently have an active eczema rash on your face - Eczema rash must affect your eyes or eyelids - if eligible to participate, you will be asked to discontinue wearing contact lenses for the duration of the study Study Description: The purpose of this clinical study is to see how effective an investigational medication is at helping to treat a condition known as atopic keratoconjunctivitis, or AKC. AKC presents as red, itchy eyes and eye lids and is commonly seen in patients with facial eczema that affects the eyes and/or eye lids. The study medication is currently FDA approved to treat several inflammatory conditions and is being explored as a new therapy option for patients with AKC. You will be asked to attend a screening visit to determine if you are eligible to enroll in the study. If enrolled, you will receive either the injectable medication being tested in this study or a placebo to be administered every 7 days for a total of 16 weeks of treatment. Your total participation will last approximately 4 months and you will be asked to attend 7 doctor’s visits. After 4 months, participants will be offered the chance to join an optional open-label period where they will receive the study medication for up to an additional 16 weeks of treatment. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated up to $1575 for 7 visits or $2475 for 11 visits for time and travel. During study visits, you will complete various procedures and tests that will include visual tests, eye exams, vitals, and physical exams. The doctor’s office conducting the study will be able to provide you with more information about the study requirements.
SmartAdv

About: SmartAdv

SmartAdv prides itself on service and support as our state of the art infrastructure operates 24/7/365 and our account managers are at your beck and c ... Read More

SmartAdv prides itself on service and support as our state of the art infrastructure operates 24/7/365 and our account managers are at your beck and call to provide concierge service to all of our customers. Get incredible offers to monetize websites and campaigns, in addition to generating high click-through and sales ratios, not to mention excellent payouts and terms.

Build traffic in popular verticals and increase your profitability. We work with you to setup and maintain your solutions so you can focus on your business and increase your profits, without wasting time on technology.

Join the industry's premier network and come grow with us!
Read Less

Similar offers

var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ''; var plc378612 = window.plc378612 || 0; var plc378614 = window.plc378614 || 0; var plc378613 = window.plc378613 || 0; var plc389895 = window.plc389895 || 0; var plc389896 = window.plc389896 || 0; var plc389897 = window.plc389897 || 0; var plc389898 = window.plc389898 || 0; var plc389899 = window.plc389899 || 0; var plc389900 = window.plc389900 || 0; var plc378615 = window.plc378615 || 0; var plc378616 = window.plc378616 || 0; var plc378623 = window.plc378623 || 0; var masterObject = { topAd: { id: 378612, counter: plc378612 }, homepageAd2: { id: 378614, counter: plc378614 }, sidebarTopAd: { id: 378613, counter: plc378613 }, sidebarAd1: { id: 389895, counter: plc389895 }, sidebarAd2: { id: 389896, counter: plc389896 }, sidebarAd3: { id: 389897, counter: plc389897 }, sidebarAd4: { id: 389898, counter: plc389898 }, sidebarAd5: { id: 389899, counter: plc389899 }, sidebarAd6: { id: 389900, counter: plc389900 }, sidebarBottomAd: { id: 378615, counter: plc378615 }, bottomAd: { id: 378616, counter: plc378616 }, offerTopAd: { id: 378623, disabled: false, counter: plc378623 } }; Object.keys(masterObject).forEach(function(key) { var entry = masterObject[key]; var element = document.getElementById(key); if (element && !entry.disabled) { document.getElementById(key).innerHTML = `
`; AdButler.ads.push({ handler: function(opt) { AdButler.register( 161318, entry.id, [728,90], 'placement_' + entry.id + '_' + opt.place, opt ) }, opt: { place: entry.counter++, keywords: abkw, domain: 'servedbyadbutler.com', click: 'CLICK_MACRO_PLACEHOLDER' } }); } });